Inhibition of Gelatinases (MMP-2 and MMP-9) by Withania somnifera Phytochemicals Confers Neuroprotection in Stroke: An In Silico Analysis

[1]  Sanjay Kumar,et al.  In Silico Prioritization, Synthesis and In Vitro Evaluation of Tembamide Analogs for Anti-HIV Activity , 2017 .

[2]  R. Patnaik,et al.  Withania somnifera Phytochemicals Confer Neuroprotection by Inhibition of the Catalytic Domain of Human Matrix Metalloproteinase-9 , 2017 .

[3]  R. Patnaik,et al.  Exploring neuroprotective potential of Withania somnifera phytochemicals by inhibition of GluN2B-containing NMDA receptors: An in silico study. , 2016, Medical hypotheses.

[4]  Z. Shah,et al.  Withania somnifera Improves Ischemic Stroke Outcomes by Attenuating PARP1-AIF-Mediated Caspase-Independent Apoptosis , 2015, Molecular Neurobiology.

[5]  Swet Chand Shukla,et al.  Resveratrol inhibits matrix metalloproteinases to attenuate neuronal damage in cerebral ischemia: a molecular docking study exploring possible neuroprotection , 2015, Neural regeneration research.

[6]  K. Jain,et al.  Comprehensive Report on Phytochemistry and Pharmacological Prominence of Withania somnifera , 2015 .

[7]  Z. Shah,et al.  Withania somnifera: a pre-clinical study on neuroregenerative therapy for stroke , 2015, Neural regeneration research.

[8]  J. Bielewicz,et al.  The significance of matrix metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke , 2014, The International journal of neuroscience.

[9]  B. N. Tomlinson,et al.  Selective Inhibition of Matrix Metalloproteinase-9 Attenuates Secondary Damage Resulting from Severe Traumatic Brain Injury , 2013, PloS one.

[10]  L. Kaczmarek,et al.  MMP-9 Inhibition: a Therapeutic Strategy in Ischemic Stroke , 2013, Molecular Neurobiology.

[11]  V. Thawani,et al.  Effects of Withania somnifera in patients of schizophrenia: A randomized, double blind, placebo controlled pilot trial study , 2013, Indian journal of pharmacology.

[12]  S. Lakhan,et al.  Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke , 2013, Front. Neurol..

[13]  A. Mishra,et al.  An in-silico strategy to explore neuroprotection by quercetin in cerebral ischemia: a novel hypothesis based on inhibition of matrix metalloproteinase (MMPs) and acid sensing ion channel 1a (ASIC1a). , 2012, Medical hypotheses.

[14]  S. Kaul,et al.  Water Extract from the Leaves of Withania somnifera Protect RA Differentiated C6 and IMR-32 Cells against Glutamate-Induced Excitotoxicity , 2012, PloS one.

[15]  À. Rovira,et al.  MMP‐2/MMP‐9 Plasma Level and Brain Expression in Cerebral Amyloid Angiopathy‐Associated Hemorrhagic Stroke , 2012, Brain pathology.

[16]  E. Hamel,et al.  Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver , 2012, Proceedings of the National Academy of Sciences.

[17]  P. Leeson,et al.  Drug discovery: Chemical beauty contest , 2012, Nature.

[18]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[19]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[20]  R. Bischoff,et al.  Physiology and pathophysiology of matrix metalloproteases , 2010, Amino Acids.

[21]  Guohong Li,et al.  Molecular insights and therapeutic targets for blood–brain barrier disruption in ischemic stroke: Critical role of matrix metalloproteinases and tissue-type plasminogen activator , 2010, Neurobiology of Disease.

[22]  H. Bitterman,et al.  Different activation forms of MMP-2 oppositely affect the fate of endothelial cells. , 2010, American journal of physiology. Cell physiology.

[23]  John H. Zhang,et al.  Matrix metalloproteinases inhibition provides neuroprotection against hypoxia‐ischemia in the developing brain , 2009, Journal of neurochemistry.

[24]  S. Rajasankar,et al.  Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse. , 2009, Journal of ethnopharmacology.

[25]  Anil Kumar,et al.  Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease. , 2009, Journal of medicinal food.

[26]  William A Banks,et al.  Characteristics of compounds that cross the blood-brain barrier , 2009, BMC neurology.

[27]  T. Olsen,et al.  Hemorrhagic and Ischemic Strokes Compared: Stroke Severity, Mortality, and Risk Factors , 2009, Stroke.

[28]  Sudha Seshadri,et al.  Gender Differences in Stroke Incidence and Poststroke Disability in the Framingham Heart Study , 2009, Stroke.

[29]  Anthony O'Hagan,et al.  The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the future , 2009, BMC neurology.

[30]  Sarah Crunkhorn.  Stroke: Widening the therapeutic window? , 2008, Nature Reviews Drug Discovery.

[31]  S. Kulkarni,et al.  Withania somnifera: An Indian ginseng , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[32]  S. Kulkarni,et al.  Effect of Withania somnifera Dunal root extract against pentylenetetrazol seizure threshold in mice: possible involvement of GABAergic system. , 2008, Indian journal of experimental biology.

[33]  R. M. Adibhatla,et al.  Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. , 2008, CNS & neurological disorders drug targets.

[34]  L. Mishra.  Scientific Basis for Ayurvedic Therapies , 2007 .

[35]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[36]  D. Hess,et al.  Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke , 2006, BMC Neuroscience.

[37]  B. Rosen,et al.  Role of matrix metalloproteinases in delayed cortical responses after stroke , 2006, Nature Medicine.

[38]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Neuroblast Cell Migration from the Subventricular Zone after Stroke , 2006, The Journal of Neuroscience.

[39]  James F Blake,et al.  Identification and evaluation of molecular properties related to preclinical optimization and clinical fate. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).

[40]  G. Rosenberg,et al.  Multiple roles for MMPs and TIMPs in cerebral ischemia , 2005, Glia.

[41]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[42]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[43]  H. Bramlett,et al.  Pathophysiology of Cerebral Ischemia and Brain Trauma: Similarities and Differences , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[44]  B. Baxter,et al.  Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. , 2003, Journal of vascular surgery.

[45]  Xin Hu,et al.  Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction. , 2003, Journal of molecular graphics & modelling.

[46]  D. Corbett,et al.  Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases , 2003, Annals of neurology.

[47]  Naranamangalam R Jagannathan,et al.  Evaluation of Withania somnifera in a middle cerebral artery occlusion model of stroke in rats , 2003, Clinical and experimental pharmacology & physiology.

[48]  W. Stallings,et al.  Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor. , 2002, Biochimica et biophysica acta.

[49]  A. Henney,et al.  Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. , 2002, Journal of molecular biology.

[50]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[51]  H. Matsuda,et al.  Structures of withanosides I, II, III, IV, V, VI, and VII, new withanolide glycosides, from the roots of Indian Withania somnifera DUNAL. and inhibitory activity for tachyphylaxis to clonidine in isolated guinea-pig ileum. , 2001, Bioorganic & medicinal chemistry.

[52]  Jeffrey W. Smith,et al.  MT1-MMP Initiates Activation of pro-MMP-2 and Integrin αvβ3 Promotes Maturation of MMP-2 in Breast Carcinoma Cells , 2001 .

[53]  M. Michaelides,et al.  Recent advances in matrix metalloproteinase inhibitors research. , 1999, Current pharmaceutical design.

[54]  A. Gearing,et al.  Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.

[55]  R. Poorman,et al.  Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors. , 1999, Journal of medicinal chemistry.

[56]  M F Sanner,et al.  Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.

[57]  G. Rosenberg,et al.  Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. , 1998, Stroke.

[58]  H. Maeda,et al.  Human Matrix Metalloprotease Activation by Insults of Bacterial Infection Involving Proteases and Free Radicals , 1998, Biological chemistry.

[59]  A. Clark,et al.  Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia , 1997, Neuroscience Letters.

[60]  R. Babine,et al.  MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .

[61]  H. V. Van Wart,et al.  Structure and expression of neutrophil gelatinase cDNA. Identity with type IV collagenase from HT1080 cells. , 1992, The Journal of biological chemistry.

[62]  J. Enghild,et al.  Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. , 1992, The Journal of biological chemistry.

[63]  N. K. Abubakirov,et al.  Withanolides in the vegetable kingdom , 1977, Chemistry of Natural Compounds.

[64]  Arthur J Olson,et al.  Small-molecule library screening by docking with PyRx. , 2015, Methods in molecular biology.

[65]  Aparna Raghavan.  Neuroprotective Potential of Withania Somnifera in Cerebral Ischemia , 2014 .

[66]  Vaishali M Patil,et al.  Specificity of binding with matrix metalloproteinases. , 2012, Experientia supplementum.

[67]  Ncbi.  National Center for Biotechnology Information , 2008 .

[68]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[69]  E. C. Ritchie,et al.  Gender Differences , 1981, Language in Society.

[70]  F. Abalan,et al.  A study of digestive absorption in four cases of Down's syndrome. Down's syndrome, malnutrition, malabsorption, and Alzheimer's disease. , 1990, Medical hypotheses.